Statement by Knights of Columbus CEO Carl Anderson on HHS Action to End NIH Research on Fetal Tissue Obtained from Abortions
NEW HAVEN, Conn., June 5, 2019 /PRNewswire/ -- The following is a statement from Carl Anderson, Supreme Knight, Knights of Columbus, on HHS Action to End NIH Research on Fetal Tissue Obtained from Abortions:
"The Knights of Columbus applauds the action taken today by the Department of Health and Human Services (HHS) to end research by the National Institutes of Health (NIH) using fetal tissue obtained from elective abortions. Over the past several years, NIH has spent millions of taxpayer dollars pursuing this unethical research and today's announcement is an important step ensuring that public funding is not used to support a practice that depends on the destruction of innocent human life. We thank the department for this important action and encourage HHS to ensure that all grants maintain a respect for human life." ? Carl Anderson, Supreme Knight, Knights of Columbus
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...
The "Drug Delivery Companies Compendium 2024" directory has been added to ResearchAndMarkets.com's offering.
The Drug Delivery Companies Compendium is a cost-effective, time-saving product that answers all of your questions about Drug Delivery...
Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its...
Biomed Israel, the premier international Life Science and HealthTech conference in Israel, will take place on May 21-23, 2024, at the David InterContinental Hotel in Tel Aviv, Israel. The event presents a unique opportunity for global healthcare and...
